Payment overview · 2025
General Payments
$19,658.74
66 reported records · 20 companies
Healthcare provider profile · identity verified
Christopher W. Pollock, M.D.
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · KNOXVILLE, TN · NPI 1306953260
Verified facts
What the public records show
CMS Open Payments records show Christopher W. Pollock, M.D. received $19,658.74 in general payments during 2025 across 66 reported records.
ConvaTec Inc. accounted for 88.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $17,400.00 | 88.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$834.17 | 4.2% | 30 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $306.01 | 1.6% | 2 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $222.76 | 1.1% | 3 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $184.66 | 0.9% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $147.62 | 0.8% | 10 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $133.70 | 0.7% | 2 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $74.40 | 0.4% | 2 | 2025 |
| Medline Industries LP | Unresolved — no canonical attribution shown | $62.30 | 0.3% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $48.73 | 0.2% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $46.28 | 0.2% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $31.08 | 0.2% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $28.33 | 0.1% | 1 | 2025 |
| Curonix LLC | Unresolved — no canonical attribution shown | $25.95 | 0.1% | 1 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $22.46 | 0.1% | 1 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $21.50 | 0.1% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $18.03 | 0.1% | 1 | 2025 |
| ARGON MEDICAL DEVICES, INC. | Unresolved — no canonical attribution shown | $17.88 | 0.1% | 1 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $17.17 | 0.1% | 1 | 2025 |
| CashFlow Solutions, LLC | Unresolved — no canonical attribution shown | $15.71 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Debt forgiveness | $17,400.00 | 2 |
| Food and Beverage | $2,215.95 | 63 |
| Travel and Lodging | $42.79 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $17,400.00 | 2 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $510.57 | 11 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $222.76 | 3 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Iliac Branch Endoprosthesis Normalized: gore excluder iliac branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $184.66 | 1 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $173.08 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $173.08 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $137.68 | 11 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $132.93 | 1 | 2025 |
Source payment records
|
|||||
| IGT Devices Systems Undivided Normalized: igt devices systems undivided |
Device | Philips North America LLC | $103.28 | 7 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $96.95 | 1 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $90.05 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $74.40 | 2 | 2025 |
Source payment records
|
|||||
| CONCERTOTM Normalized: concertotm |
Device | Medtronic, Inc. | $53.30 | 4 | 2025 |
Source payment records
|
|||||
| STRAVIX MESH Normalized: stravix mesh |
Biological | Smith+Nephew, Inc. | $46.28 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX PL Normalized: stravix pl |
Biological | Smith+Nephew, Inc. | $46.28 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $43.65 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 5F VCS Normalized: cardiva vascade 5f vcs |
Device | CARDIVA MEDICAL, INC. | $29.73 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $28.33 | 1 | 2025 |
Source payment records
|
|||||
| SPIDERFX Normalized: spiderfx |
Device | Medtronic, Inc. | $28.32 | 2 | 2025 |
Source payment records
|
|||||
| PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A Normalized: pns freedom 4a permanent neurostimulator receiver kit channel a |
Device | Curonix LLC | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| Laser service and other Normalized: laser service and other |
Device | Philips North America LLC | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| IV Other Normalized: iv other |
Device | Philips North America LLC | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| CLOT MANAGEMENT Normalized: clot management |
Device | ARGON MEDICAL DEVICES, INC. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| LYMPHA PRESS OPTIMAL PLUS(US) BT Normalized: lympha press optimal plus us bt |
Device | CashFlow Solutions, LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| PCD-51 731A (US) - White Normalized: pcd 51 731a us white |
Device | CashFlow Solutions, LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| PCD-52 737A (US) White Normalized: pcd 52 737a us white |
Device | CashFlow Solutions, LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT AV Normalized: in pact av |
Device | Medtronic, Inc. | $7.35 | 1 | 2025 |
Source payment records
|
|||||
| Image Guided Therapy Devices Service Undivided Normalized: image guided therapy devices service undivided |
Device | Philips North America LLC | $5.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Cephalexin | Cephalexin | 200 | 115 |
| Naproxen | Naproxen | 183 | 107 |
| Alprazolam | Alprazolam | 156 | 95 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 43 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 42 | 28 |
| Eliquis | Apixaban | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $19,658.74 · 66 records | ConvaTec Inc. | ABRE, ARTEGRAFT VASCULAR GRAFT, Alto Abdominal Stent Graft System, CARDIVA VASCADE 5F VCS, CARDIVA VASCADE 6/7F VCS, CLOT MANAGEMENT, CONCERTOTM, ENDOCROSS Device, ENROUTE Transcarotid Neuroprotection System, Flexitouch Plus, GORE EXCLUDER Iliac Branch Endoprosthesis, HAWKONE, IGT Devices Systems Undivided, IN.PACT AV, INNOVAMATRIX AC, IV Other, Image Guided Therapy Devices Service Undivided, Indigo System, LYMPHA PRESS OPTIMAL PLUS(US) BT, Laser service and other, Nimbl, PCD-51 731A (US) - White, PCD-52 737A (US) White, PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A, RotarexS 6 F x 135 cm, SPIDERFX, STRAVIX MESH, STRAVIX PL, Senza, Serrantor, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Torus Stent Graft System, VENASEAL, Varithena Administration Pack, Venovo | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error